Characterizing cerebral toxoplasmosis in non‑HIV immunocompromised adults at Strasbourg University Hospital.
Retrospective Descriptive Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital From 2010 to 2023
This project will collect clinical information on adults with weakened immune systems (excluding HIV) who have cerebral toxoplasmosis to see which diagnostic methods, treatments, and preventive steps work best.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07299500 on ClinicalTrials.gov |
What this trial studies
This observational cohort will include adult, non‑HIV immunocompromised patients with at least one positive toxoplasmosis PCR identified at Strasbourg University Hospital. Investigators will compile clinical, imaging, laboratory, treatment, and outcome data to describe how the disease presents and is managed in these groups. The work aims to estimate how many patients are affected and to identify patterns that could inform diagnosis, therapy, and prevention outside the HIV setting. Patients who decline data reuse, those with congenital toxoplasmosis, or isolated ocular disease in immunocompetent people will be excluded from analysis.
Who should consider this trial
Good fit: Adults (18 or older) who are immunocompromised for any reason (e.g., solid organ or stem cell transplant, hematologic malignancy, cancer therapy, immunosuppressive drugs, autoimmune or primary/secondary immunodeficiency) and have at least one positive toxoplasmosis PCR and are HIV‑negative.
Not a fit: Patients who are HIV‑positive, have congenital toxoplasmosis, have isolated ocular toxoplasmosis while immunocompetent, or who refuse reuse of their data are not eligible and would not benefit from this cohort's findings.
Why it matters
Potential benefit: If successful, this could lead to clearer, evidence‑based guidance for diagnosing, treating, and preventing cerebral toxoplasmosis in non‑HIV immunocompromised patients.
How similar studies have performed: Management of cerebral toxoplasmosis is well established in people with HIV and there are recent recommendations for hematopoietic stem cell transplant recipients, but systematic data across other non‑HIV immunocompromised groups remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (≥18 years) * Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary). * At least one positive toxoplasmosis PCR test (regardless of tissue) Exclusion Criteria: * Subject who has expressed opposition to the reuse of their data for scientific research. * HIV positive * Congenital toxoplasmosis * Isolated ocular toxoplasmosis in immunocompetent individuals
Where this trial is running
Strasbourg
- Service d'immunologie clinique - Hôpitaux Universitaires de Strasbourg — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Mathilde HERBER, MD
- Email: mathilde.herber@chru-strasbourg.fr
- Phone: 33 3.69.55.13.99
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.